Prosecution Insights
Prosecution Insights
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (17%) |
| §112 only | 2 (33%) |
| Double-patenting only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EDGINGTONGIORDANO, FRANCESCA | 1 | 72.3% | +30.2% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.5% |
| LEE, YIE CHIA | 1 | 74.2% | +39.8% |
| STONEBRAKER, ALYSSA RAE | 1 | 55.8% | +48.8% |
| SKELDING, ZACHARY S | 1 | 59.7% | +41.4% |
| FISCHER, JOSEPH | 1 | 43.0% | +45.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257872 | METHOD FOR TREATING SJOGREN'S SYNDROME USING TACI-FC FUSION PROTEIN | LEE, YIE CHIA | 52d overdue |
| 18511857 | USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER | EDGINGTONGIORDANO, FRANCESCA | — |
| 18450966 | USE OF ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN TREATMENT OF SPECIFIC BREAST CANCER | PUTTLITZ, KARL J | — |
| 18250726 | METHOD FOR TREATING IGA NEPHROPATHY WITH TACI-FC FUSION PROTEIN | STONEBRAKER, ALYSSA RAE | — |
| 17594768 | BISPECIFIC FUSION PROTEIN AND APPLICATION THEREOF | SKELDING, ZACHARY S | — |
| 17052079 | TACI-FC FUSION PROTEINS AND USES THEREOF | FISCHER, JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1646 | 1 |
| 1600 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18511857 | USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER | EDGINGTONGIORDANO, FRANCESCA | — | DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18450966 | USE OF ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN TREATMENT OF SPECIFIC BREAST CANCER | PUTTLITZ, KARL J | 1646 | DPOther | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18257872 | METHOD FOR TREATING SJOGREN'S SYNDROME USING TACI-FC FUSION PROTEIN | LEE, YIE CHIA | 1642 | §112 | Final Rejection | 52d overdue | Pending | Jun 15, 2023 |
| 18250726 | METHOD FOR TREATING IGA NEPHROPATHY WITH TACI-FC FUSION PROTEIN | STONEBRAKER, ALYSSA RAE | 1642 | §102 | Final Rejection | — | Pending | Apr 26, 2023 |
| 17594768 | BISPECIFIC FUSION PROTEIN AND APPLICATION THEREOF | SKELDING, ZACHARY S | 1600 | §112 | Non-Final OA | — | Pending | Oct 28, 2021 |
| 17052079 | TACI-FC FUSION PROTEINS AND USES THEREOF | FISCHER, JOSEPH | 1658 | DP | Final Rejection | — | Pending | Oct 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial